Skip to main content
$127.08 -2.85 (-2.19%) At close · Jul 29
Market Cap
$25.96B
Shares
199.78M

Incyte Corp Earnings Call Transcripts

Every quarterly earnings call for Incyte Corp (INCY) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q2
2026-07-28
Incyte Corp Q2 FY2026 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Goldman Sachs Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-08
Incyte Conference Call
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-28
Incyte Corp Q1 FY2026 Earnings Call
Confident tone Geographic and international growth Core business expansion beyond Jakify Pipeline and regulatory milestones
Revenue
$1.27B
▲ 20.9% YoY
Diluted EPS
$1.47
▲ 83.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-11
Barclays 28th Annual Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-10
Incyte Corp Q4 FY2025 Earnings Call
Confident tone 2025 Financial Performance and 2026 Outlook Pipeline Risks and Clinical Readouts Jakafi Franchise and Jakafi XR
Revenue
$1.51B*
▲ 27.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Incyte Corp Q3 FY2025 Earnings Call
Confident tone Hem/onc innovation focus (MPNs, 989, 617) Niktimvo launch trajectory Jakafi performance and guidance raise
Revenue
$1.37B
▲ 20% YoY
Diluted EPS
$2.11
▲ 290.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
Incyte Corp Q2 FY2025 Earnings Call
Confident tone Pipeline catalysts (989, povorcitinib, axatilimab) Jakafi demand outlook and IRA Niktimvo launch
Revenue
$1.22B
▲ 16.5% YoY
Diluted EPS
$2.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-29
Incyte Corp Q1 FY2025 Earnings Call
Confident tone Jakafi commercial performance and guidance raise Financial results and operating expenses KRAS G12D inhibitor competitive landscape
Revenue
$1.05B
▲ 19.5% YoY
Diluted EPS
$0.80
▲ 6.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-10
Incyte Corp Q4 FY2024 Earnings Call
Confident tone Jakafi (ruxolitinib) performance and guidance Opzelura growth and pediatric atopic dermatitis launch 2025 pipeline catalysts and pivotal readouts
Revenue
$1.18B*
▲ 16.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Incyte Corp Q3 FY2024 Earnings Call
Confident tone Opzelura growth and geographic expansion Jakafi commercial performance and guidance raise CDK2 inhibitor competitive positioning
Revenue
$1.14B
▲ 23.8% YoY
Diluted EPS
$0.54
▼ 28.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-30
Incyte Corp Q2 FY2024 Earnings Call
Confident tone Opzelura growth and expansion Jakafi commercial performance and guidance Pipeline transformation and prioritization
Revenue
$1.04B
▲ 9.3% YoY
Diluted EPS
$-2.04
▼ 326.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
Incyte Corp Q1 FY2024 Earnings Call
Positive tone Jakafi performance Opzelura growth Pipeline launches by 2030
Revenue
$880.89M
▲ 8.9% YoY
Diluted EPS
$0.75
▲ 650% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-13
Incyte Corp Q4 FY2023 Earnings Call
Confident tone Opzelura launch momentum Jakafi commercial performance and 2024 guidance Pipeline and ten high-impact launches by 2030
Revenue
$1.01B*
▲ 9.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Incyte Corp Q3 FY2023 Earnings Call
Revenue
$919.02M
▲ 11.6% YoY
Diluted EPS
$0.76
▲ 52% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Incyte Corp Q2 FY2023 Earnings Call
Revenue
$954.61M
▲ 4.7% YoY
Diluted EPS
$0.90
▲ 25% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Incyte Corp Q1 FY2023 Earnings Call
Revenue
$808.67M
▲ 10.3% YoY
Diluted EPS
$0.10
▼ 41.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-07
Incyte Corp Q4 FY2022 Earnings Call
Revenue
$926.70M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Incyte Corp Q3 FY2022 Earnings Call
Revenue
$823.30M
▲ 1.3% YoY
Diluted EPS
$0.50
▼ 39% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Incyte Corp Q2 FY2022 Earnings Call
Revenue
$911.40M
Diluted EPS
$0.72
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Incyte Corp Q1 FY2022 Earnings Call
Revenue
$733.24M
▲ 21.3% YoY
Diluted EPS
$0.17
▼ 29.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-08
Incyte Corp Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Incyte Corp Q3 FY2021 Earnings Call
Revenue
$812.99M
Diluted EPS
$0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Incyte Corp Q2 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Incyte Corp Q1 FY2021 Earnings Call
Revenue
$604.72M
▲ 6.4% YoY
Diluted EPS
$0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-09
Incyte Corp Q4 FY2020 Earnings Call
Revenue
$789.51M
▲ 36.3% YoY
Diluted EPS
$0.68
▲ 33.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Incyte Corp Q3 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Incyte Corp Q2 FY2020 Earnings Call
Revenue
$705.71M
▲ 33.2% YoY
Diluted EPS
$0.67
▲ 39.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Incyte Corp Q1 FY2020 Earnings Call
Revenue
$568.51M
▲ 14.2% YoY
Diluted EPS
$-3.33
▼ 808.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-13
Incyte Corp Q4 FY2019 Earnings Call
Revenue
$579.39M
▲ 9.6% YoY
Diluted EPS
$0.51
▲ 59.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–30 of 30 earnings calls
Key facts CIK 879169 CUSIP 45337C102 13F (30d) 265 filings 234 filers Visit website